gene therapy

Ascidian

Biotech

Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B

Ascidian and Lilly signed a collaboration worth up to $1.9 billion to develop RNA exon editing therapeutics for genetic kidney diseases.

Will Maddox Jun 3, 2026 7:00am

Child jumping on trampoline

Regenxbio reaps pivotal win for Duchenne gene therapy

May 14, 2026 7:25am

Assorted cleaning supplies sitting on a wooden table

Astellas thins early pipeline, swaps out struggling gene therapy

Apr 27, 2026 10:38am

research deal two people shaking hands in lab

Astellas, Dyno unearth $15M muscle disorder capsid

Apr 8, 2026 8:00am

step up climb ladder sky hang on rung

Regenxbio gene therapy passes interim test as pivotal data loom

Mar 12, 2026 5:49am

FDA stop sign

Senior FDA official fires back at uniQure amid controversy

Mar 5, 2026 3:33pm